Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder

Recruiting now · Phase 4

Conditions studied: Attention Deficit Disorder With Hyperactivity

In brief

Methylphenidate (MPH) is the first-line pharmacological treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Nevertheless, there is considerable interindividual variability regarding the dose required, tolerability and response rates to MPH. The aim of this study is to address the clinical and genetic predictors of MPH treatment outcomes in ADHD.

Key facts

Study ID

NCT02951754

Run by

Hospital de Clinicas de Porto Alegre

People needed

600

Starts

2002-02-01

Expected to finish

2032-12-01

Last updated by the study team

2016-11-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• White Brazilian of European descent
• Fulfillment of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV) diagnostic criteria for ADHD
• Eligibility to immediate-release MPH (IR-MPH) treatment

You may not qualify if…

• Contraindication for IR-MPH use
• Current stimulant treatment
• Evidence of a clinically significant neurological disease that might affect cognition (e.g., delirium, dementia, epilepsy, head trauma, and multiple sclerosis)
• Current or past history of psychosis
• Estimated intelligence quotient score lower than 70

Where it is running

• Program on Attention-Deficit/Hyperactivity Disorder (PRODAH); Hospital de Clínicas de Porto Alegre — Porto Alegre, Rio Grande do Sul, Brazil (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.